Assessing bioresorbable coronary devices Methods and parameters

JACC: Cardiovascular Imaging

Volumn 7, Issue 11, 2014, Pages 1130-1148

  Garcia Garcia, Hector M ^a   Serruys, Patrick W ^a   Campos, Carlos M ^a,b   Muramatsu, Takashi ^a   Nakatani, Shimpei ^a   Zhang, Yao Jun ^a   Onuma, Yoshinobu ^a   Stone, Gregg W ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Bioresorbable scaffolds; Coronary; Imaging; Intravascular ultrasound; Multislice computed tomography; Optical coherence tomography

Indexed keywords

ANGIOCARDIOGRAPHY; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR STENT; FRACTIONAL FLOW RESERVE; GRAY SCALE ECHOGRAPHY; HISTOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STENT MALAPPOSITION; THREE DIMENSIONAL IMAGING; ADVERSE EFFECTS; ANIMAL; BIODEGRADABLE IMPLANT; COMPUTER ASSISTED TOMOGRAPHY; DEVICES; ENDOSCOPIC ECHOGRAPHY; HUMAN; MATERIALS TESTING; OBSERVER VARIATION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROCEDURES; PROSTHESIS; REPRODUCIBILITY; TIME; TREATMENT OUTCOME;

BIOMATERIAL; CARDIOVASCULAR AGENT;

ABSORBABLE IMPLANTS; ANIMALS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; HUMANS; MATERIALS TESTING; OBSERVER VARIATION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84922544746     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2014.06.018     Document Type: Review

References (49)

1. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade Eur Heart J 2012;33:16-25b.
2. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18: 70-4.
3. Onuma Y, Serruys PW, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;78:3-12.
4. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6-And 12-month clinical and multimodality imaging results. J Am Coll Cardiol Intv 2014;7:89-99.
5. Wentzel JJ, Whelan DM, van der Giessen WJ, et al. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-95.
6. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. J Am Coll Cardiol Intv 2010;3:1190-8.
7. Gomez-Lara J, Brugaletta S, Farooq V, et al. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. J Am Coll Cardiol Intv 2011;4:789-99.
8. Waksman R, Prati F, Bruining N, et al. Serial observation of drug-eluting absorbable metal scaffold: multi-imaging modality assessment. Circ Cardiovasc Interv 2013;6:644-53.
9. Holzmann S. Endothelium-induced relaxation by acetylcholine associated with larger rises in cyclic GMP in coronary arterial strips. J Cyclic Nucleotide Res 1982;8:409-19.
10. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-70.
11. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy Eur Heart J 2012;33:1325-33.
12. Choi G, Cheng CP, Wilson NM, Taylor CA. Methods for quantifying three-dimensional deformation of arteries due to pulsatile and nonpulsatile forces: implications for the design of stents and stent grafts. Ann Biomed Eng 2009;37:14-33.
13. Kim HJ, Jansen KE, Taylor CA. Incorporating autoregulatory mechanisms of the cardiovascular system in three-dimensional finite element models of arterial blood flow. Ann Biomed Eng 2010;38: 2314-30.
14. Kim HJ, Vignon-Clementel IE, Coogan JS, Figueroa CA, Jansen KE, Taylor CA. Patientspecific modeling of blood flow and pressure in human coronary arteries. Ann Biomed Eng 2010; 38:3195-209.
15. Serruys PW, Girasis C, Papadopoulou SL, Onuma Y. Non-invasive fractional flow reserve: scientific basis, methods and perspectives. Euro-Intervention 2012;8:511-9.
16. Koo BK, Erglis A, Doh JH, et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVERFLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Cardiol 2011;58:1989-97.
17. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998;19:1214-23.
18. Otake H, Shite J, Ako J, et al. Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. J Am Coll Cardiol Intv 2009;2:459-66.
19. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369:1869-75.
20. Campos CM, Muramatsu T, Iqbal J, et al. Bioresorbable drug-eluting magnesium-Alloy scaffold for treatment of coronary artery disease. Int J Mol Sci 2013;14:24492-500.
21. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of the bioabsorbable everolimuseluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008;52: 1616-20.
22. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014;9:1271-84.
23. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122:2301-12.
24. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88.
25. Gogas BD, Serruys PW, Diletti R, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimuseluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the firstin-man ABSORB Cohort B Trial. J Am Coll Cardiol Intv 2012;5:656-65.
26. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention 2007;3:113-20.
27. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012;5: 620-32.
28. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008;198:39-48.
29. Sathyanarayana S, Carlier S, Li W, Thomas L. Characterisation of atherosclerotic plaque by spectral similarity of radiofrequency intravascular ultrasound signals. EuroIntervention 2009;5:133-9.
30. Garcia-Garcia HM, Gogas BD, Serruys PW, Bruining N. IVUS-based imaging modalities for tissue characterization: similarities and differences. Int J Cardiovasc Imaging 2011;27:215-24.
31. Okubo M, Kawasaki M, Ishihara Y, et al. Development of integrated backscatter intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol 2008;34: 655-63.
32. Okubo M, Kawasaki M, Ishihara Y, et al. Tissue characterization of coronary plaques: comparison of integrated backscatter intravascular ultrasound with virtual histology intravascular ultrasound. Circ J 2008;72:1631-9.
33. Schaar JA, Regar E, Mastik F, et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 2004;109:2716-9.
34. Schaar JA, De Korte CL, Mastik F, et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 2003;108: 2636-41.
35. Bruining N, de Winter S, Roelandt JR, et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasoundderived parameters a feasibility study. J Am Coll Cardiol Intv 2010;3:449-56.
36. Bruining N, Verheye S, Knaapen M, et al. Three-dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity. Catheter Cardiovasc Interv 2007;70:968-78.
37. García-García HM, Muramatsu T, Nakatani S, et al. Serial optical frequency domain imaging in STEMI patients: the follow-upreport ofTROFI study. Eur Heart J Cardiovasc Imaging 2014;15:987-95.
38. Onuma Y, Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122:2288-300.
39. Okamura T, Onuma Y, Garcia-Garcia HM, et al. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. J Am Coll Cardiol Intv 2010;3:836-44.
40. Farooq V, Onuma Y, Radu M, et al. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention 2011;7:386-99.
41. Farooq V, Serruys PW, Heo JH, et al. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. J Am Coll Cardiol Intv 2013;6: 523-32.
42. Gutierrez-Chico JL, Serruys PW, Girasis C, et al. Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. Int J Cardiovasc Imaging 2012;28:467-78.
43. Gomez-Lara J, Brugaletta S, Diletti R, et al. Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheter Cardiovasc Interv 2012; 79:890-902.
44. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. Int J Mol Sci 2011; 12:4250-70.
45. van Alst M, Eenink MJ, Kruft MA, van Tuil R. ABC's of bioabsorption: application of lactide based polymers in fully resorbable cardiovascular stents. EuroIntervention 2009;5 Suppl F: F23-7.
46. Onuma Y, Dudek D, Thuesen L, et al. Fiveyear clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB Cohort A trial. J Am Coll Cardiol Intv 2013;6: 999-1009.
47. Nørgaard BL, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps). J Am Coll Cardiol 2014;63:1145-55.
48. Nieman K, Serruys PW, Onuma Y, et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol 2013;62: 1813-4.
49. Brugaletta S, Gomez-Lara J, Diletti R, et al. Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2012;79: 219-28.